Heart Rhythm 2024 Unveils its Late Breaking Trial Program

Heart Rhythm Conference has revealed 5 late-breaking trial sessions to be presented in May. 

HRS 2024 will take place from the 17th to the 19th May at the Boston Convention and Exhibition Center in Boston. Access the full programme here.


Late Breaking Clinical Trials and Science - CIEDs

Friday 17th May, 11:30am – 12:30pm

  • LEADR in Defibrillation: Global Pivotal Trial Results of a Novel, Small-Diameter Defibrillation Lead Designed for Reliability – Presented by Dr George Crossley
  • Assessment of Primary Prevention Patients Receiving an ICD- Systematic Evaluation of ATP: APPRAISE ATP– Presented by Dr Claudio Schuger
  • Transvenous Extraction of Conduction System Pacing leads: An international Multicenter (TECSPAM) Study– Presented by Dr Pugazhendi Vijayaraman
  • Impact of Iodine Impregnated Barrier Dressings on Cardiac Implantable Device Infections: a Randomized Controlled Trial (BARRIER-PROTECT, NCT:04591366) – Presented by Dr Alper Aydin


Late Breaking Clinical Trials and Science - Ablation

Friday 17th May, 16:00 – 17:00pm

  • A Randomized Controlled Trial of a Lattice-Tip Mapping and Ablation System with Radiofrequency and Pulsed Field Energy for Treating Persistent Atrial Fibrillation– Presented by Dr Elad Anter
  • Long-term Outcomes in Long Standing Persistent Atrial Fibrillation Following Catheter or Thoracoscopic Surgical Ablation Using Continuous Monitoring: 3-year Follow-up of the CASA-AF Randomised Controlled Trial– Presented by Dr Tom Wong
  • Real world data collection in subjects treated with the FARAPULSE Pulsed Field Ablation system (FARADISE) – Presented by Dr Lucas Boersma
  • Long-term Safety and Effectiveness After Paroxysmal Atrial Fibrillation Pulsed Field Ablation from the U.S. Multicenter admIRE Study – Presented by Dr Vivek Reddy


Late Breaking Clinical Trials and Science - Innovation

Saturday 18th May, 09:30 – 10:30am

  • Tailored Cardiac Ablation Procedure for Persistent Atrial Fibrillation Guided by Artificial Intelligence: The TAILORED-AF Randomized Clinical Trial – Presented by Dr Isabel Deisenhofer
  • One Year Safety and Performance Outcomes from a Clinical Study of a Dual-Chamber Leadless Pacemaker System – Presented by Dr Reinoud Knops
  • Tachycardia therapy and Endpoint Results of the First Modular, Intra-body, Communicating Subcutaneous Defibrillator-Leadless Pacemaker System: MODULAR ATP Interim Cohort – Presented by Dr Reinoud Knops
  • AF Ablation Using a Novel “Single-Shot” Map-and-Ablate Spherical Array Pulsed Field Ablation Catheter: 1-Year Outcomes of the First-in-Human PULSE-EU Trial – Presented by Dr Vivek Reddy


Late Breaking Clinical Trials and Science - Ablation

Saturday 18th May, 14:00 – 15:00pm

  • Mediterranean diet enriched with extravirgin olive oil reduced risk of tachyarrhythmia recurrence after atrial fibrillation ablation: the PREDIMAR trial – Presented by Dr Maria Barrio-Lopez
  • Impact of Pulsed Field vs Thermal Ablation on One-Year Atrial Arrhythmia Burden – Sub-analysis of the ADVENT Trial – Presented by Dr Vivek Reddy
  • Short- and Long-term Clinical Outcomes of Radiofrequency Catheter Ablation in Paroxysmal Atrial Fibrillation. Results From the Prospective Multicenter REAL-AF Registry – Presented by Dr Paul Zei
  • Safety and Effectiveness of Pulsed Field Ablation for Atrial Fibrillation in Patients with Heart Failure: A MANIFEST-PF Registry Sub-analysis – Presented by Dr Mohit Turagam


Late Breaking Clinical Trials and Science - CIEDs

Sunday 19th May, 09:30 – 10:30am

  • Impact of vigorous exercise in the Long QT Syndrome by genotype, age, and sex: Data from the Lifestyle and Exercise in Long QT Syndrome Registry (LIVE-LQTS) – Presented by Dr Rachel Lampert
  • Left Bundle Branch Area Pacing using a Stylet Driven, Retractable Helix Lead: Results from a Prospective, Multicenter Trial (The BIO-CONDUCT Study) – Presented by Dr Larry Chinitz
  • Early Cardiac Resynchronization Therapy for Patients with Moderately Reduced Ejection Fraction and Left Bundle Branch Block – Presented by Dr Yong-Mei Cha
  • Efficacy and Safety of Apixaban Versus Aspirin According to CHA2DS2-VASc Score in Patients with Subclinical Atrial Fibrillation in ARTESiA – Presented by Dr Jeffrey Healey
  • Outcomes with and without oral anticoagulation in patients with prior stroke and device-detected atrial fibrillation. The NOAH-AFNET 6 trial – Presented by Dr Paulus Kirchhof